

News Release

Lonza Group Ltd Announces Results of Annual General Meeting Annual General Meeting Accepts All Motions Proposed by Board of Directors

- Shareholders elected the proposed new Board members Barbara Richmond and Juergen Steinemann
- Peter Wilden will leave the Board of Directors as announced, all other Board members re-elected
- 252 shareholders attended, representing 47.51% of the share capital
- A dividend of CHF 2.15 per share will be paid out as of 25 April 2014
- More than 90% of shareholders supported each of the proposed motions

Basel, Switzerland, 16 April 2014 – Today's Annual General Meeting of Lonza Group Ltd, led by the Chairperson of the Board of Directors, Rolf Soiron, was attended by 252 shareholders. They represented 47.51% of the share capital.

The Board members standing for re-election (Rolf Soiron, Patrick Aebischer, Werner Bauer, Thomas Ebeling, Jean-Daniel Gerber, Margot Scheltema and Antonio Trius) were all elected for a further term in office of one year. The proposed new members, Barbara Richmond and Juergen Steinemann, were newly elected to the Board for a term in office of one year. After many years of service, Peter Wilden will leave the Board of Directors as previously announced.

The shareholders strongly supported all other motions proposed by the Board of Directors, including among others the consultative approval of the Remuneration Report, the election of the Chairperson Rolf Soiron, the election of the members of the Nomination and Compensation Committee and the revision of the Articles of Association to align them with the requirements of the Swiss Ordinance Against Excessive Compensation by Public Corporations.

A dividend of CHF 2.15 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out on 25 April 2014.

For further information, please see the short form minutes of the Lonza Annual General Meeting under [the following link](#) (select "Annual General Meeting").

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking

News Release

water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza's stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Group Ltd
Head Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Head Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
Fax +41 61 316 9840
constance.ward@lonza.com